Wegovy Expands Globally With Oral Tablets, Public Health Coverage Debates, and Manufacturing Investments Titelbild

Wegovy Expands Globally With Oral Tablets, Public Health Coverage Debates, and Manufacturing Investments

Wegovy Expands Globally With Oral Tablets, Public Health Coverage Debates, and Manufacturing Investments

Jetzt kostenlos hören, ohne Abo

Details anzeigen

Saisonale Sparangebote | 0,99 € pro Monat für die ersten 3 Monate

Danach 6,99 €/Monat. Bedingungen gelten. Monatlich kündbar.
# Wegovy's Next Chapter: Pills, Pricing Wars & Billion-Euro Decisions **Episode Description:** Wegovy is no longer just a weekly injection — it's becoming a global pharmaceutical battleground. In this episode, we unpack the biggest semaglutide headlines reshaping obesity treatment, healthcare policy, and pharma competition worldwide. We dive into Ireland's health technology assessment recommending Wegovy for public reimbursement — and the staggering €4.4 billion five-year cost projection that comes with it. We head to South Korea, where Novo Nordisk is seeking national insurance coverage amid surging prescriptions and new local competitors entering the weight-loss drug market at lower prices. Then we explore the rise of **oral semaglutide**, newly approved in the EU, and how Eli Lilly's rival pill Foundayo could trigger a head-to-head battle for the future of obesity pills. We also look inside Novo Nordisk's highly automated Danish manufacturing facility, where a tenfold investment increase is powering global supply. Plus: new clinical data from the Step Up study suggests Wegovy may reduce liver fat in nearly 90% of patients — hinting at benefits that go far beyond weight loss. From Bahrain's approval of the oral tablet to looming Novo Nordisk earnings reports, this episode connects the dots on what's next for Wegovy, Mounjaro, and the rapidly evolving GLP-1 drug market. **Topics covered:** - Ireland's HSE Wegovy reimbursement decision & cost analysis - South Korea's insurance review and rising GLP-1 competition - EU approval of oral Wegovy vs. Eli Lilly's Foundayo - Novo Nordisk's manufacturing expansion and AI-driven production - New Step Up study findings on liver fat reduction - Bahrain's oral semaglutide approval - What's next for pricing, Some great Deals https://amzn.to/49SJ3Qs For more check out http://www.quietplease.ai
adbl_web_anon_alc_button_suppression_t1
Noch keine Rezensionen vorhanden